Vaccine Adjuvants Market Report 2023: Increasing Prevalence of Infectious Diseases

According to Precision Business Insights' (PBI) latest report the vaccine adjuvants market size was valued at USD 1.53 billion in 2022 and is poised to grow at a x% CAGR during the forecast period 2023-29. The global vaccine adjuvants market presents several opportunities and is shaped by key trends. The increasing focus on pandemic preparedness and emerging infectious diseases provides opportunities for the development of adjuvanted vaccines. Advancements in adjuvant technologies, such as toll-like receptor agonists and nanoparticle-based adjuvants, offer the potential for improved vaccine efficacy. The growing demand for therapeutic vaccines, particularly in cancer immunotherapy, creates opportunities for adjuvanted vaccine development. Rising investments in research and development by key market players and government organizations drive innovation in adjuvant formulations. Additionally, the shift towards personalized medicine and targeted vaccine development open new avenues for tailored adjuvant strategies. Furthermore, the rising global immunization initiatives and increased public awareness of vaccine benefits fuel the demand for adjuvanted vaccines.

View the detailed report description here - https://www.precisionbusinessinsights.com/market-reports/global-vaccine-adjuvants-market

The vaccine adjuvants market is segmented based on by product, by usage, by disease type and geography.
1) By Product
Mineral Salt-based Adjuvant,
Tensoactive Adjuvants,
Adjuvant Emulsions,
Liposome Adjuvants,
Carbohydrate Adjuvants,
Bacteria-derived Adjuvants,
Virus-like Particles (VLP),
Others

2) By Usage
Active Immunostimulants,
Carriers,
Vehicle Adjuvants

3) By Disease Type
Infectious Disease,
Cancer

4) By Application
Research Applications,
Commercial Applications.

Infectious Disease Segment Dominate the Vaccine Adjuvants Market:
The infectious disease segment is anticipated to dominate the global vaccine adjuvants market. With the increasing prevalence of infectious diseases worldwide, there is a growing need for effective vaccines. Adjuvants play a crucial role in enhancing the immune response and efficacy of vaccines against infectious pathogens. Adjuvant vaccines for diseases such as influenza, hepatitis, and human papillomavirus (HPV) have gained significant traction. Additionally, the ongoing research and development efforts for adjuvanted vaccines against emerging infectious diseases further contribute to the prominence of the infectious disease segment in the global vaccine adjuvants market.

Asia Pacific Leads the Global Vaccine Adjuvants Market:
Asia Pacific, the Vaccine Adjuvants market holds a major market share in 2022 and the market is expected to grow at a significant CAGR during the forecast period due to increasing healthcare expenditure, growing awareness about preventive healthcare, and rising initiatives for immunization programs. The region's large population and expanding middle-class contribute to the demand for adjuvanted vaccines and drive market growth.

Request Sample: https://www.precisionbusinessinsights.com/request-sample/?product_id=17173

Strategic New Product Launches, Mergers, Acquisitions, and Agreements are the key strategies adopted by market players:
The vaccine adjuvants market further reveals that the key players increasingly adopting strategies such as the launch of newer products, frequent product approvals, and long-term alliances to improve market revenue share and gaining significant geographic presence across the region. In March 2023, Novavax Inc., announced the launch of its new COVID-19 vaccine, called NVX-CoV2373. NVX-CoV2373 is a protein-based vaccine that uses an adjuvant called Matrix-M to boost the immune response to the vaccine. The vaccine has been shown to be safe and effective in clinical trials, and it is currently under review by the U.S. Food and Drug Administration (FDA). In April 2023, Croda International PLC announced the launch of its new adjuvant, called AS04-adjuvant. AS04-adjuvant is a combination of two different adjuvants that have been shown to be safe and effective in clinical trials. The adjuvant is designed to be used in a variety of different vaccines, including vaccines against infectious diseases, cancer, and allergies.

The key players in the vaccine adjuvants market report are GlaxoSmithKline PLC, Croda International PLC, Merck KGaA, Novavax Inc., Adjuvance Technologies Inc., Adjuvatis, Agenus Inc., Brenntag SE, Chemtrade Logistics Inc., Invivogen.

Contact:
Mr. Satya
Precision Business Insights | Toll-Free: +1 866 598 1553
Email: sales@precisionbusinessinsights.com
Kemp House, 152 - 160 City Road, London EC1V 2NX
Website: https://precisionbusinessinsights.com/ | D U N S® Number: 852781747

About Precision Business Insights:
We are a market research company that strives to provide the highest quality market research insights. Our diverse market research experts are enthusiastic about market research and therefore produce high-quality research reports. We have over 500 clients with whom we have a good business partnership and capacity to provide in-depth research analysis for more than 30 countries. In addition to deliver more than 150 custom solutions, we already have accounts with the top five medical device manufacturers.

Precision Business Insights offers a variety of cost-effective and customized research services to meet particular research requirements. We are a leading research service provider because of our extensive database built by our experts and the services we provide.

This release was published on openPR.